The Business of Biofabrication

On April 20, Eli Lilly announced a definitive agreement to acquire Kelonia Therapeutics for $3.25 billion upfront and up to $7 billion including milestones. The asset: a proprietary in vivo gene delivery platform that reprograms T-cells inside the body.

For the cell therapy manufacturing sector, this deal is a signal worth sitting with.

What Kelonia built

Kelonia’s core technology is iGPS®, an in vivo gene placement system that uses engineered lentiviral-based particles to enter T-cells directly inside the patient’s body and deliver CAR-T programming. The lead programme, KLN-1010, generates anti-BCMA CAR-T cells in vivo and targets multiple myeloma.

Current approved CAR-T therapies are ex vivo: you harvest T-cells from the patient, ship them to a manufacturing facility, engineer them, quality-test them, ship them back, and infuse them. The process takes weeks, costs hundreds of thousands of dollars per patient, and requires specialised CDMO infrastructure at every step.

Kelonia’s approach skips all of that. The viral vector is the factory. You infuse the patient once and the T-cells are programmed in place.

The manufacturing disruption thesis

If in vivo CAR-T works at scale, and that is still an if, it removes the manufacturing bottleneck that has constrained ex vivo cell therapy since the beginning. No apheresis scheduling. No vein-to-vein time. No CDMO capacity crunch. No cold-chain logistics for personalised cell products.

That is potentially very bad for the ex vivo cell therapy manufacturing industry, CDMOs, bioreactor suppliers, closed-system bioprocessing companies, and very good for viral vector manufacturers who produce the in vivo delivery agents.

Lilly paying $3.25 billion upfront for an early-clinical-stage company is a statement of conviction that this disruption is coming. It follows a similar bet Lilly made with another in vivo CAR-T company, suggesting a deliberate strategic accumulation of this technology.

The biofabrication read

In vivo cell reprogramming validates the broader living-medicine thesis, the idea that biological programming can be delivered as a drug, without external manufacturing of living cells. Companies building at the biofabrication–cell-therapy intersection should be tracking this closely: the commercial case for ex vivo manufacturing is strong today, but the competitive pressure from in vivo approaches will intensify as clinical data accumulates.

Source: BioSpace, April 20 2026